Welcome to our dedicated page for Concentrix SEC filings (Ticker: CNXC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Concentrix Corporation鈥檚 constant stream of cross-border acquisitions and CX platform launches turns every filing into a labyrinth of goodwill schedules and multi-currency revenue tables. If you have ever asked, 鈥淗ow do I find the Concentrix quarterly earnings report 10-Q filing?鈥� or 鈥淲here are Concentrix insider trading Form 4 transactions posted in real time?鈥�, you already know the challenge. Each report can hide critical details on client concentration, digital-service margins, and Webhelp integration costs.
Stock Titan eliminates that struggle. Our AI reads every page the moment it hits EDGAR, then delivers plain-English answers for understanding Concentrix SEC documents with AI. Need the Concentrix annual report 10-K simplified? We highlight CX segment revenue, amortization of acquired intangibles, and geographic risk in seconds. Curious about Concentrix Form 4 insider transactions real-time? Instant alerts show executive stock transactions Form 4 alongside context. Even sudden announcements鈥擟oncentrix 8-K material events explained鈥攁rrive with concise AI summaries so you grasp the impact before markets react.
Here is what you can explore today:
- Concentrix earnings report filing analysis that compares quarter-over-quarter client-segment growth
- Detailed proxy statement executive compensation disclosures, including equity grants tied to CX performance
- Historical Concentrix insider trading Form 4 transactions to spot buying or selling trends
- AG真人官方-time updates on every filing type鈥�10-Q, 10-K, 8-K, S-8 and more鈥攅ach one SEC filings explained simply
Whether you monitor material outsourcing contracts or track how foreign-exchange swings affect margins, Stock Titan鈥檚 expert analysis surfaces the numbers that matter and keeps you ahead of the next disclosure.
Schedule 13G Overview: The joint filing discloses that Kanen Wealth Management LLC, its managing member David L. Kanen, and two affiliated investment vehicles鈥�Philotimo Fund LP and Philotimo Focused Growth & Income Fund (PHLOX)鈥攃ollectively own 381,805 shares of AYTU BioPharma, Inc. (AYTU) common stock, representing approximately 6.2 % of the 6,170,246 shares outstanding as of 1 May 2025.
The ownership is split as follows: Philotimo Fund holds 255,810 shares (4.1 %), PHLOX holds 125,995 shares (2.0 %), while Kanen Wealth Management and Mr. Kanen are deemed to beneficially own the aggregate total by virtue of their control positions. All voting and dispositive powers are reported as shared; no individual entity has sole authority over the shares. The filing is made pursuant to Rule 13d-1(c), indicating a passive investment intent. Certifications clarify the securities were not acquired to influence or change control of the issuer.
Investor take-aways: 1) A single concentrated investment adviser has crossed the 5 % threshold, adding a noteworthy institutional holder to AYTU鈥檚 register. 2) Although passive, the group鈥檚 stake could still provide support for future capital raises or governance matters given AYTU鈥檚 relatively small float. 3) No new purchase price, cost basis, or transactional timeline beyond the 14 May 2025 鈥渆vent date鈥� is disclosed, limiting insight into buying momentum.
MGIC Investment Corp. (MTG) 鈥� Form 4 insider transaction
President & COO Salvatore A. Miosi disclosed the sale of 30,000 shares of common stock on 01-Jul-2025 at a weighted-average price of $28.152 per share, generating roughly $0.84 million in proceeds. The disposition was executed under a Rule 10b5-1 trading plan adopted on 06-Mar-2025, indicating the sale was pre-scheduled and not necessarily driven by near-term information.
After the transaction, Miosi directly owns 279,401.361 shares and indirectly controls 384,844 shares via a family trust, maintaining a sizable equity stake. No derivative security activity was reported, and the filing contains no references to earnings, major corporate events, or strategic changes.
The filing primarily records a routine adjustment to the executive鈥檚 equity exposure; in isolation, it is unlikely to materially affect the company鈥檚 fundamental outlook.
Form 4 Overview 鈥� Torrid Holdings Inc. (CURV)
On June 30, 2025 Sycamore Partners Torrid, L.L.C. and its affiliated investment vehicles (collectively, 鈥淪ycamore鈥�) filed a Form 4 reporting a significant change in their beneficial ownership of Torrid Holdings common stock. The filing covers transactions executed on June 26, 2025.
- Total shares disposed: 15,680,908.
- Disposition breakdown: (i) 9,650,000 shares sold to the public in a registered secondary offering, and (ii) 6,030,908 shares repurchased directly by the issuer in a privately-negotiated buyback.
- Price: $3.31625 per share (net of underwriting discount) for both legs of the transaction.
- Remaining ownership: 58,295,694 common shares are still reported as beneficially owned by Sycamore.
- Reporting persons: Seven Sycamore-related entities and Mr. Stefan Kaluzny (managing partner) jointly filed; each remains a >10 % owner and disclaims beneficial ownership beyond pecuniary interest.
No derivative securities were reported. The transaction code 鈥淪鈥� confirms it was a sale of non-derivative equity.
Key takeaways for investors
- Sycamore reduced its stake by roughly 15.7 million shares but still retains a sizeable holding, potentially keeping meaningful influence over the company.
- The simultaneous issuer share repurchase offsets part of the public float increase and may signal Board approval of capital return at the stated price.
- The $3.31 transaction price provides an observable valuation reference for recent large-block trades.
Concentrix (Nasdaq: CNXC) filed an 8-K (Item 2.02) announcing it has released fiscal Q2 2025 results for the quarter ended May 31 2025. The company furnished, but did not file, a press release (Exhibit 99.1) containing the detailed financial statements and commentary. No numerical data, guidance, or strategic commentary is included in the 8-K text itself. The disclosure is strictly limited to the existence of the press release and therefore carries limited information for investors without referencing Exhibit 99.1. The filing reconfirms that the information is considered "furnished," not "filed," preserving safe-harbor protections.
FAQ
What is the current stock price of Concentrix (CNXC)?
What is the market cap of Concentrix (CNXC)?
What does Concentrix Corporation do?
Which industries does Concentrix serve?
How does Concentrix differentiate itself from competitors?
What is Concentrix's global presence?
What role does technology play in Concentrix's services?
What is iX Hello by Concentrix?
What is Concentrix's approach to digital transformation?
Who are Concentrix's main competitors?
